Skip to content

Comparison Between Two Different Protocols in Polycystic Ovary Symdrome Women Undergoing Intra-cytoplasmic Injection

CLASSICAL ANTAGONIST PROTOCOL IN COMPARISON WITH AGONIST STOP PROTOCOL IN Polycystic Ovary Symdrome WOMEN UNDERGOING Intra-cytoplasmic Injection TRIAL: a Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04094467
Enrollment
150
Registered
2019-09-19
Start date
2019-12-07
Completion date
2021-01-31
Last updated
2020-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome

Brief summary

Stein and Leventhal were the first to recognize an association between the presence of polycystic ovaries and signs of hirsutism and amenorrhea (eg,oligomenorrhea, obesity), After women diagnosed with Stein-Leventhal syndrome underwent successful wedge resection of the ovaries, their menstrual cycles became regular, and they were able to conceive. As a consequence, a primary ovarian defect was thought to be the main culprit, and the disorder came to be known as polycystic ovarian disease.

Interventions

0.25 mg subcutaneous injection daily for 6 days

DRUGLeuprolide Acetate

0.1 mg subcutaneous injection daily for 12 days

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

1. Women under 35 years with polycystic ovary syndrome criteria 2. Normal male semen parameters 3. Normal tubes either by hysterosalpingography &/or laparoscopy 4. Free from other endocrine abnormalities

Exclusion criteria

1. NON polycystic ovary syndrome Criteria 2. More than 35 years 3. Abnormal semen parameters 4. Pathological tube& pelvic factor 5. Other endocrine disorders

Design outcomes

Primary

MeasureTime frameDescription
The difference in clinical pregnancy rate in both groups6 weeksultrasound detection of fetal heart pulsations

Countries

Egypt

Contacts

Primary ContactMohammed Smeeh, MSc
drmohamedhemida84@gmail.com00201001737769

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026